Miruvor
Sign up
The short answer

What studies of Symptom-tracking apps and wearables (Visible) found

8papers on Symptom-tracking apps and wearables (Visible)
25people in 1 study testing Symptom-tracking apps and wearables (Visible) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Both together: C Might help, very uncertain

Based on the strongest evidence, the randomised trial (very low certainty): 3 findings, all C.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Symptom-tracking apps and wearables (Visible) might help some people with long COVID and ME/CFS studied together, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 8 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Symptom-tracking apps and wearables (Visible) · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Both together

Symptoms

Fatigue1 study · 25 people received Symptom-tracking apps and wearables (Visible) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all).

The randomised trial47 randomised · at two and six months post-enrolment

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of symptom-tracking apps and wearables (Visible) on fatigue in ME/CFS or long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    SF-36 Fatigue/energy (E) 36-Item Short Form Survey
    Effect
    better (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 25 people received Symptom-tracking apps and wearables (Visible) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all); one study saw it get worse, without a test against chance.

The randomised trial47 randomised · at two and six months post-enrolment

Too little to say about low mood or anxiety.

Too little to say: low mood or anxiety got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
  • One study saw it get worse, without a test against chance
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    SF-36 Emotional well-being (EmW) 36-Item Short Form Survey
    Effect
    worse (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Pain1 study · 25 people received Symptom-tracking apps and wearables (Visible) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all); one study saw it get worse, without a test against chance.

The randomised trial47 randomised · at two and six months post-enrolment

Too little to say about pain.

Too little to say: pain got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
  • One study saw it get worse, without a test against chance
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    SF-36 Pain (P) 36-Item Short Form Survey
    Effect
    worse (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 25 people received Symptom-tracking apps and wearables (Visible) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all).

The randomised trial47 randomised · at two and six months post-enrolment

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of symptom-tracking apps and wearables (Visible) on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    SF-36 Physical Functioning (PF) 36-Item Short Form Survey
    Effect
    better (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Quality of life1 study · 25 people received Symptom-tracking apps and wearables (Visible) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all).

The randomised trial47 randomised · at two and six months post-enrolment

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of symptom-tracking apps and wearables (Visible) on quality of life in ME/CFS or long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    SF-36 Role limitations due to EmP (EmP) 36-Item Short Form Survey
    Effect
    better (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Overall symptoms1 study · 25 people received Symptom-tracking apps and wearables (Visible) Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (47 in all); one study saw it get worse, without a test against chance.

The randomised trial47 randomised · at two and six months post-enrolment

Too little to say about overall symptoms.

Too little to say: overall symptoms got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (47 in all)
  • One study saw it get worse, without a test against chance
See the 1 study
  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study (2025)

    People in the study
    47 randomised
    Dose
    —
    Outcome
    Good Day/Bad Day Questionnaire – good days Good Day/Bad Day Questionnaire
    Effect
    worse (not tested)
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Studies of combinations

Outcomes that only studies of Symptom-tracking apps and wearables (Visible) given together with other treatments looked at. Shown, not graded: they can’t tell what Symptom-tracking apps and wearables (Visible) did alone.

Sleep Long COVID

Combination: 15-week post-COVID outpatient program + Symptom-tracking apps and wearables (Visible) + Pacing and the energy envelope + Strength training + CBT and psychotherapy + Meditation, yoga, breathwork1 in the study

Feasibility of Using a Commercially Available Smartwatch to Advance Outcomes for Patient With Post-Acute Sequelae of COVID-19 (PASC): Case Report (2025): Sleep Duration, better (not tested).

Shown, not counted: Symptom-tracking apps and wearables (Visible) was given together with other treatments.

Daily functioning Long COVID

Combination: 15-week post-COVID outpatient program + Symptom-tracking apps and wearables (Visible) + Pacing and the energy envelope + Strength training + CBT and psychotherapy + Meditation, yoga, breathwork1 in the study

Feasibility of Using a Commercially Available Smartwatch to Advance Outcomes for Patient With Post-Acute Sequelae of COVID-19 (PASC): Case Report (2025): 6 Minute Walk Test (6MWT) distance, better (not tested).

Shown, not counted: Symptom-tracking apps and wearables (Visible) was given together with other treatments.

Side effects

Stopping because of side effects1 study
Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Anxiety or irritability1 study

All papers

  1. Pacing with a heart rate monitor for people with myalgic encephalomyelitis/chronic fatigue syndrome and long COVID: a feasibility study2025 · randomised trial · 47 randomised
    Summary

    This mixed-methods feasibility study asked whether pacing with a heart rate monitor (HRM) could be studied in people with ME/CFS and long COVID (LC). Forty-seven participants were recruited via the Stockport ME/CFS and LC support group and online forums and randomized to a control group (22) or an intervention group (25). For eight weeks, the intervention group used an HRM with weekly online HRM pacing advice; the control group received weekly online pacing advice and did not have an HRM for eight weeks. Assessments included a ten-minute stand test, questionnaires, accelerometry, heart rate variability and lactate. There were no serious adverse events. Five ME/CFS participants could not complete the ten-minute stand test due to severe symptoms and reported PEM. Five ME/CFS participants in the intervention group did not use the HRM for the whole eight weeks. Three control and one intervention participant dropped out after the two-month intervention phase. The ten-minute stand test and stationary/light accelerometry showed no discernible change; both groups had a slight increase in moderate activity and moderate-to-vigorous activity. Heart rate variability showed a 1% recovery increase in the control group versus 0% in the intervention group, and a 7% physiological stress decrease in the intervention group versus a 1% increase in the control group. Reasons for stopping included skin reactions, anxiety in one person with LC, and general health got worse. 89% of the intervention group planned to continue HRM immediately after the intervention and 66% of all interviewees planned to continue at six months.

  2. Pacing with a heart rate monitor for people with Myalgic Encephalomyelitis and Long Covid2022 · randomised trial · 47 randomised
    Summary

    This feasibility study examined pacing with a heart rate monitor (HRM) for people with ME/CFS and long COVID. Forty-seven participants (32 ME/CFS and 15 long COVID) were recruited via the Stockport ME/CFS and LC support group and online forums. Twenty-two were randomized to a control group and 25 to an intervention group. For eight weeks, the intervention group used a Garmin® wrist device or a Polar® Verity Sense arm band with the Visible app plus weekly online HRM pacing advice; the control group received weekly online pacing advice. Measures included a 10-minute stand test, questionnaires, accelerometry, heart rate variability and lactate. Follow-up was at two and six months post-enrolment. There were no discernible changes in blood pressure, heart rate, and oxygen saturation before and after the intervention. Both groups showed no discernible change in stationary or light behaviour but a slight increase in moderate activity and moderate-to-vigorous activity. The control group had a 1% (14–15%) increase in recovery versus 0% (10–10%) in the intervention group; the intervention group had a 7% (73–66%) decrease in physiological stress versus a 1% (64–65%) increase in controls. Average lactate decreased in both groups (control 3.7–2.7; intervention 3.7–2.9). No serious adverse events were reported. Five ME/CFS participants could not complete the 10-minute stand test due to severe symptoms and reported PEM after it. Three control and one intervention participant dropped out after the two-month intervention phase. Authors state limitations include a small sample and limited geographical recruitment.

  3. Feasibility, Adherence, Acceptance and Usability of a Multimodal Telemonitoring for Pediatric Post-COVID Syndrome: A Bicentric Pilot Study.2026 · no comparison group · 30 in the study
    Summary

    This exploratory bicentric pilot study assessed a multimodal telemonitoring concept for pediatric Post-COVID Syndrome in patients aged 12–17 years recruited from two outpatient university clinics in Bielefeld and Munich, Germany. Thirty patients participated and all completed the 12-week monitoring period without dropouts. The intervention combined a patient app, a portable spirometer, a smartwatch, patient-reported outcome measures, chat and video consultations, and a telemedicine platform; monitoring lasted three months. No control group was included. Adherence was reported as 4.6 days per week (66%) for spirometry, 3.4 days per week (49%) for pulse data and 3.3 days per week (47%) for step data. Completed symptom questionnaires were 411/480 (86%), video consultations 58/60 (97%), chat use 30/30 (100%), and a 1-minute Sit-to-Stand test was performed in 44/58 (76%) of video consultations. Usability scores were 81.25 for patients and 75.42 for parents. Therapeutic benefit was completely or partially perceived by 57% (16/28) of patients and 71% (20/28) of parents; overall ratings were ‘very good’ in 54% (15/28) of patients and 61% (17/28) of parents, and only two patients rated it ‘rather poor’. No adverse events occurred; two patients expressed dissatisfaction due to wristband skin irritation. The authors state limitations including no control group, a short observation period and small sample size, and technical smartwatch issues.

  4. Wearable technology in the management of complex chronic illness: preliminary survey results on self-reported outcomes.2025 · no comparison group · 1,301 in the study
    Summary

    This study was an online survey of users of the Visible Plus mobile application with a Polar Verity Sense™ HR monitor; the authors state they did not include a control group. The survey was circulated to n = 2,636 randomly selected subscribers from a total pool of n = 4,537 subscribers, yielding n = 1,301 responses. Participants self-identified as having ME/CFS only (n = 534, 42%), LC only (n = 396, 31%), ME/CFS and LC (n = 236, 18%), or another illness (n = 122, 10%). Eligibility required a minimum of 30 days of wearable HR data. The survey asked about feeling of control, physical activity levels, understanding of energy budget, frequency and severity of PEM episodes, activity without PEM trigger, energy management, and daily activities participation. Among users with 30+ days of wearable data, 77% reported improvements associated with app use; the improved column for Q1 feeling of control was 85.25 (1,109), Q3 understanding of energy budget 93.71 (1,220), Q4 PEM frequency 60.64 (789), Q5 PEM severity 59.47 (774), Q7 energy management 89.83 (1,168), and Q8 daily activities 50.31 (655). Worsened responses were recorded, e.g. Q1 significantly worsened 0.08 (1) and somewhat worsened 1.16 (15). Among users who connected the armband in March 2024, 86% continued 30 days later; for January 2024, 75% were still using it after 90 days. There were no statistically significant differences between 30+ and 60+ or 90+ days. Participants who discontinued before 30 days were excluded.

  5. Utilising Continuous HRV Biofeedback Data for Autonomic Nervous System Regulation in ME/CFS Relapse Management2026 · case report · 1 in the study · preprint
    Summary

    This case report describes one patient with ME/CFS for relapse management in standard client sessions who used continuous heart rate variability (C-HRV) biofeedback with an ECG-grade Firstbeat Life device, health coaching and HRV specialist interpretation for an 11-week intervention, alongside pacing, sleep optimisation, task modification and autonomic regulation strategies. There was no comparison group. The paper reports within-patient changes from baseline to 11 weeks: baseline HRV (RMSSD) rose from 24 ms to 33 ms (+37.5%); Sleep Quality Score from 37/100 to 56/100 (+51.4%); Stress and Recovery Balance Score from 23/100 to 48/100 (+108.7%); and Subjective Wellbeing from 24% to 34% (+41.7%). On the Firstbeat Wellbeing survey, 'I feel that I sleep enough' was 40% at Week 1 and 80% at Week 11 (difference 40); 'I don't feel stressed' was 80% and 80% (0); 'My days include breaks and time for recovery' 80% and 100% (20); 'I feel alert and energetic most of the time' 20% and 40% (40); 'I feel well at the moment' 20% and 40% (60). Harms reported included a sharp drop in overall HRV and near-total absence of nocturnal PNS recovery during a 10-day low dose naltrexone trial, and a complete lack of PNS recovery during sleep on three separate palmitoylethanolamide trials; a severe immune flare occurred immediately after the 11-week intervention. Withdrawals for harms were not reported. The authors state the findings are from a single case (N=1) and may not be representative.

  6. Feasibility of Using a Commercially Available Smartwatch to Advance Outcomes for Patient With Post-Acute Sequelae of COVID-19 (PASC): Case Report2025 · combination: given with other treatments · 1 in the study
    Summary

    This retrospective case report explored whether smartwatch use can augment rehabilitation of a patient with Post-Acute Sequelae of COVID-19 (PASC) including fatigue, post-exertional malaise, brain fog, weakness, and limited ability to complete IADLs and work/life roles. One adult completed a 15-week post-COVID outpatient program (11 visits each for physical, occupational, and speech therapies) at an outpatient physical rehabilitation hospital. A Garmin Venu SQ2 watch was provided at the second visit to monitor daily steps, heart rate, sleep, and stress. Treatment included pacing, graded endurance and strength training, cognitive therapy, and diaphragmatic breathing, with smartwatch data integrated to guide exercise intensity, stress management, and sleep hygiene. There was no comparison group. Between the first and last therapy weeks, average daily Steps were 8,667 vs. 7,419, average daily Stress 32.1 vs. 32.3, Sleep Duration 6.6 vs. 7.2 hours, and Resting Heart Rate 60.2 vs. 57.7 bpm. Between admission and discharge, 6MWT distance was 401 vs. 571 m, STS repetitions 10 vs. 16, dominant arm Grip Strength 36 vs. 56 lbs; RPE decreased (6MWT 7 vs. 2; STS 5 vs. 3), dyspnea decreased (5 vs 2; STS 5 vs. 3), and DePaul PEM frequency was 2.0 vs. 0.4 and severity 2.2 vs. 0.6. No harms or withdrawals were reported. The authors state no limitations.

  7. Wearable Devices Enable Long COVID Patients to Decrease Symptom Severity: A Case Series From Pilot User Testing.2025 · combination: given with other treatments · 11 in the study · 9 with outcome data

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime